恆瑞醫藥(600276.SH):擬與盛迪投資、恆瑞集團設合夥企業 打造國內領先的生物醫藥創新投資平台
格隆匯6月6日丨恆瑞醫藥(600276.SH)公佈,為提升公司資本運作能力,做深公司產業佈局,公司擬與控股子公司盛迪投資、恆瑞集團簽署《上海盛迪生物醫藥私募投資基金合夥企業(有限合夥)合夥協議》,共同發起設立合夥企業。合夥企業此次認繳出資總額為20.1億元,其中盛迪投資作為普通合夥人(GP)出資1000萬元,持股比例為0.5%,公司、恆瑞集團作為有限合夥人(LP)分別出資10億元,持股比例分別為49.75%。公司資金來源為自有資金。
投資基金將根據法律法規規定及合夥協議的約定,秉持創新、價值、成長標準,圍繞醫藥健康產業開展股權投資業務,投資醫藥健康領域優質企業,重點關注生物醫藥領域的創新研發,打造培育生物醫藥產業生態圈和國內領先的生物醫藥創新投資平台。投資基金有利於滿足公司業務和戰略發展的需求,符合公司現有及未來業務發展方向,有利於公司的長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.